๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chengdu
Clinical trial register · China

Clinical Trials in Chengdu, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
West China Hospital162 AstraZeneca148 Janssen Research & Development, LLC55 Hoffmann-La Roche44 Sichuan University44
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Chengdu

1291 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
A Phase 2 in Adult Subjects With Hereditary Angioedema
NCT06846398Hereditary Angioedema (HAE)
Shanghai Argo Biopharmaceutical Co., Ltd.
Phase 2
25
Beijing, Lanzhou, Wuhan, Yantai, Chengdu, Kunming
2025-02-28
Recruiting
The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL
NCT06763055Intracerebral Hemorrhage, Spontaneous Intracerebral Hemorrhage, Supratentorial Intracerebral Haemorrhage, Acute Intracerebral Haemorrhage
The George Institute
Phase 3
2,000
Chengdu
2025-02-27
Recruiting
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
NCT06780137Small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 1/2
327
Beijing, Fuzhou, Nanjing, Shanghai, Chengdu, Hangzhou
2025-02-27
Recruiting
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
NCT06780670Prostate Cancer
Novartis Pharmaceuticals
Phase 2/3
443
Fuzhou, Wuhan, Nanjing, Shenyang, Xian, Chengdu, Beijing, Guangzhou
2025-02-27
Active, closed
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
NCT06745323Small Cell Lung Cancer (SCLC)
Amgen
Phase 2
252
Beijing, Fuzhou, Guangzhou, Harbin, Changsha, Taiyuan, Chengdu, Tianjin
2025-02-26
Recruiting
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
NCT06741644Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1/2
800
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-02-24
Active, closed
Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer
NCT06865521Colo-rectal Cancer, PD-1 Inhibitor, Akkermansia Muciniphila
West China Hospital
Not applicable
22
Chengdu
2025-02-21
Active, closed
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naรฏve Participants With Active Psoriatic Arthritis
NCT06878404Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 3
552
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Linyi
2025-02-21
By invitation
PRIor Myocardial Infarction Identification on Electrocardiogram
NCT06811194Prior Myocardial Infarction
The Third People's Hospital of Chengdu
Observational
12,000
Chengdu
2025-02-20
Recruiting
Safety and Efficacy Evaluation of Sodium Hyaluronate 32mg/ml in Improving Facial Skin Dryness and Dullness
NCT06914583Facial Dryness, Facial Dullness
IBSA Farmaceutici Italia Srl
Not applicable
500
Beijing, Changde, Chengdu, Shanghai, Xi'an
2025-02-19
Active, closed
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
NCT06727565Head and Neck Squamous Cell Carcinoma
Gilead Sciences
Phase 2
39
Chengdu, Hangzhou, Nanning, Shanghai, Wuhan
2025-02-18
Active, closed
Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT06712888Nasopharyngeal Carcinoma (NPC)
Sun Yat-sen University
Phase 3
466
Fuzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning, Guiyang, Changsha, Chengdu
2025-02-17
Recruiting
Efficacy and Safety of Cocktail of Ropivacaine for Local Infiltration Analgesia in Patients Undergoing Laparoscopic Cholecystectomy
NCT06819748Cholecystectomy, Laparoscopic, Ambulatory Surgical Procedures, Multimodal Analgesia
Sichuan Provincial People's Hospital
Not applicable
210
Chengdu
2025-02-14
Active, closed
A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest Huntington's Disease.
NCT07339514Huntington Disease
ExoRNA Bioscience
Phase 1/2
27
Guangzhou, Chengdu
2025-02-11
Recruiting
Study on the Improvement of Microcirculation in Patients With Sepsis by Vitamin B6, Vitamin B12 and Vitamin C
NCT06749756Septic Shock
Fan Zeng
Not applicable
296
Chengdu
2025-02-10
Active, closed
HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma
NCT06773130Pancreatic Ductal Adenocarcinoma (PDAC)
West China Hospital
Phase 1/2
20
Chengdu
2025-02-10
Recruiting
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
NCT06858579Chronic Inflammatory Demyelinating Polyneuropathy
Dianthus Therapeutics
Phase 3
256
Hefei, Guangzhou, Changsha, Wuhan, Chifeng, Suzhou, Beijing, Chengdu
2025-02-10
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834360Chronic Rhinosinusitis With Nasal Polyps
Sanofi
Phase 3
216
Baotou, Beijing, Chengdu, Chongqing, Hangzhou, Jinan, Jingzhou, Nanning
2025-02-06
By invitation
Development and Verification of a Screening Tool for Comprehensive Geriatric Assessment of Elderly Tumor Patients
NCT06761534Geriatric Assessment, Geriatric Patients, Patients With Cancer, Assessment Tool
Sichuan Cancer Hospital and Research Institute
Observational
678
Chengdu
2025-02-05
Recruiting
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
NCT06624670Pyoderma Gangrenosum
LEO Pharma
Phase 3
90
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Jinan, Shanghai, Shenzhen
2025-02-05
Recruiting
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
NCT06769971Small Cell Lung Cancer
Sichuan University
Phase 2
80
Chengdu
2025-02-01
Recruiting
A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC
NCT06769295Lung Cancer, Non-Small Cell
Sichuan University
Phase 2
28
Chengdu
2025-02-01
Active, closed
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000Hidradenitis Suppurativa
Novartis Pharmaceuticals
Phase 3
588
Fuzhou, Guangzhou, Wuhan, Changsha, Changchun, Shenyang, Xian, Chengdu
2025-01-31
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Hefei, Beijing, Guangzhou, Wuhan, Harbin, Changsha, Chengdu, Hangzhou
2025-01-29
Active, closed
A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)
NCT06812117Diabetic Peripheral Neuropathic Pain
Daiichi Sankyo
Observational
721
Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou
2025-01-24
Recruiting
A Study of SHR-4394 Injection in Subjects With Prostate Cancer
NCT06783829Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
240
Chengdu
2025-01-22
Not yet open
A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma
NCT06781112TPF, Immunotherapy, Nasopharyngeal Carcinoma, Phase II Clinical Study
Weiwei Zhang
Phase 2
35
Chengdu
2025-01-20
Recruiting
A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity
NCT07100210Refractory Malignant Solid Tumors, mRNA Vaccine, Interleukin
Xingchen Peng
Phase 1
6
Chengdu
2025-01-20
Recruiting
AI-Driven Cancer Diagnosis and Prediction With EHR
NCT06791473Tumor
The Eye Hospital of Wenzhou Medical University
Observational
1,000,000
Guangzhou, Chengdu, Wenzhou
2025-01-19
Active, closed
A Phase II Clinical Trial of the Safety and Efficacy of SAL0120 in Patients With Chronic Kidney Disease (CKD)
NCT07716618Chronic Kidney Disease
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Phase 2
320
Chengdu
2025-01-17
Recruiting
Evaluate the Efficacy and Safety of TTYP01 Tablets in Adolescents and Children With ASD
NCT06757504Autism Spectrum Disorder (ASD)
Shanghai Auzone Biological Technology Co., Ltd.
Phase 2
150
Beijing, Changsha, Chengdu, Nanjing, Tianjin
2025-01-13
Recruiting
Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC
NCT07748325Non-Small Cell Lung Cancer, Adjuvant Therapy, Immune Checkpoint Inhibitors
Sichuan University
Phase 2
100
Chengdu, Suining
2025-01-10
Active, closed
A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer
NCT07005336Non Small Cell Lung Cancer
TJ Biopharma Co., Ltd.
Phase 2
150
Beijing, Binzhou, Chengdu, Chongqing, Haโ€™erbin, Hefei, Jiangmen, Kunming
2025-01-09
Recruiting
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 3
750
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Guiyang
2025-01-09
Recruiting
Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia
NCT06722586Antiphospholipid (aPL)-Positive, Thrombocytopaenia
Peking University First Hospital
Phase 4
84
Changsha, Jinan, Chengdu, รœrรผmqi, Wenzhou, Beijing, Shanghai
2025-01-07
Recruiting
Assessment of the Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Patients With Major Depressive Disorder
NCT06692361Major Depressive Disorder (MDD), Depression - Major Depressive Disorder
Gang Wang
Not applicable
214
Wuhu, Beijing, Guangzhou, Shijiazhuang, Jining, Chengdu, Tianjin, Dali
2025-01-01
Not yet open
Fascia Iliaca Compartment Block and Tramadol for Analgesia in Hip Fracture
NCT06728033Hip Fractures, Ultrasound-guided Nerve Block, Perioperative Analgesia
West China Hospital
Not applicable
240
Chengdu
2025-01-01
Not yet open
Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia
NCT06643195AML
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
358
Shijiazhuang, Zhengzhou, Jinan, Chengdu
2025-01-01
Not yet open
Nano-crystalline Megestrol Acetate for Adjuvant Treatment in High-risk Head and Neck Squamous Cell Carcinoma After Surgery.
NCT06772428Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
96
Chengdu
2025-01-01
By invitation
Protective Effect of Probacine Against Negative Gut Metabolism and Organ Dysfunction After Cardiovascular Surgery (PANDA IV)
NCT04444362Cardiovascular Disease, Cardiopulmonary Bypass
Nanjing Medical University
Not applicable
500
Beijing, Guangzhou, Nanjing, Chengdu, Shanghai
2025-01-01
Not yet open
Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese Children
NCT06763315Plexiform Neurofibromas (PN)
West China Hospital
Phase 2
50
Chengdu
2025-01-01
Recruiting
Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma
NCT06798363Infantile Hemangioma
West China Hospital
Phase 2/3
32
Chengdu
2025-01-01
Not yet open
Erector Spinae Plane Block v.s Patient Controlled Analgesia in Correction Surgery for Idiopathic Scoliosis
NCT06728046Idiopathic Scoliosis, Erector Spinae Plane Block, Patient Controlled Analgesia
West China Hospital
Not applicable
40
Chengdu
2025-01-01
Recruiting
Glycemic Improvement With Team, Technology, Education and Peer Resources in Type 1 Diabetes-GLITTER Study
NCT07097805Type 1 Diabetes (T1D)
Second Xiangya Hospital of Central South University
Not applicable
3,000
Beijing, Guangzhou, Shenzhen, Luoyang, Changsha, Nanjing, Shenyang, Chengdu
2025-01-01
Not yet open
A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
NCT06774664IgA Nephropathy
Sinocelltech Ltd.
Phase 1/2
99
Baotou, Beijing, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanning
2025-01
Recruiting
XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC
NCT06742411Gastric (Stomach) Cancer
West China Hospital
Phase 1/2
57
Chengdu
2024-12-31
Not yet open
Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern)
NCT06753890Diarrhea-predominant Irritable Boewl Syndrome
Tasly Pharmaceutical Group Co., Ltd
Phase 3
520
Baoding, Beijing, Changsha, Chengde, Chengdu, Guangzhou, Hangzhou, Kaifeng
2024-12-30
Active, closed
A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection
NCT07183306Chronic Hepatitis B
Suzhou HepaThera Biotech Co., Ltd.
Phase 1/2
86
Beijing, Xiamen, Guangzhou, Qingyuan, Shanghai, Chengdu
2024-12-30
Active, closed
Efficacy and Safety of ZVS101e in Patients With Bietti 's Crystalline Dystrophy
NCT06743646Bietti Crystalline Corneoretinal Dystrophy, Bietti Crystalline Dystrophy
Chigenovo Co., Ltd
Phase 3
62
Beijing, Guangzhou, Haerbin, Zhengzhou, Shanghai, Chengdu, Tianjin, Wenzhou
2024-12-27
Recruiting
The Impact of AI-Based Fundus Imaging on Blood Glucose Control and Fundus Examination Completion Rates in Outpatient Diabetic Patients
NCT06819423Diabetes
Jie Li
Not applicable
200
Chengdu
2024-12-26
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
NCT06556394Amyotrophic Lateral Sclerosis
Ractigen Therapeutics.
Phase 1
32
Beijing, Chengdu, Hangzhou
2024-12-24
Recruiting
Hydroxychloroquine Sulfate Tablets for Radiation-induced Oral Mucositis
NCT06939582Radiation-induced Oral Mucositis
Xingchen Peng
Phase 1/2
158
Chengdu
2024-12-22
Recruiting
Theory-based Health Behaviour Change Intervention in Individuals of Metabolic Syndrome With Chronic Kidney Disease
NCT06715735Chronic Kidney Diseases, Metabolic Syndrome
Chinese University of Hong Kong
Not applicable
160
Chengdu
2024-12-20
Recruiting
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
NCT06500702Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
Sanofi
Phase 2
84
Beijing, Chengdu, Shanghai
2024-12-19
Recruiting
Phase I Study of HSK46575 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT07007910m CRPC
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
90
Chengdu
2024-12-18
Recruiting
A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors
NCT06725381Solid Malignancies
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
138
Guangzhou, Nanning, Wuhan, Changsha, Nanjing, Jinan, Linyi, Chengdu
2024-12-17
Recruiting
Multicenter Phase I Study of HRS-6208 in Patients With Solid Tumors
NCT06727812Solid Tumors
Shandong Suncadia Medicine Co., Ltd.
Phase 1
206
Nanjing, Chengdu
2024-12-17
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma
GlaxoSmithKline
Phase 3
520
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai
2024-12-16
Recruiting
A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus
NCT06741982HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy, Immunotherapy
West China Hospital
Phase 1
21
Chengdu
2024-12-15
Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094Colorectal Neoplasms
Janssen Research & Development, LLC
Phase 3
700
Beijing, Changchun, Changsha, Chengdu, Ganzhou, Guangzhou, Hangzhou, Harbin
2024-12-12
Recruiting
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors
NCT06726369Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
90
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Shanghai, Wuhan
2024-12-12
Recruiting
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
NCT06716606Connective Tissue Diseases
GlaxoSmithKline
Phase 3
514
Beijing, Chengdu, Hangzhou, Mianyang, Shanghai, Shenyang, Zhuzhou
2024-12-12
Recruiting
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
NCT05421858Candidemia, Candidiasis, Invasive
Basilea Pharmaceutica
Phase 3
450
Beijing, Bengbu, Chengdu, Guangzhou, Hangzhou, Lishui, Liuzhou, Nanchang
2024-12-11
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche
Phase 3
350
Beijing, Kunming, Changsha, Chengdu, Guangzhou, Hangzhou, Huizhou, Nanchang
2024-12-11
Recruiting
Clinical Trial of TQB3002 in Patients With Advanced Cancers
NCT06662760Advanced Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
150
Guangzhou, Shenzhen, Zhengzhou, Nanjing, Nanchang, Shanghai, Xiโ€™an, Chengdu
2024-12-09
Active, closed
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia
NCT06834932Dyslipidaemia
AstraZeneca
Phase 2/3
432
Baotou, Beijing, Bengbu, Changchun, Changde, Changsha, Changzhou, Chengdu
2024-12-06
Active, closed
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969Sjogrens Syndrome
Janssen Research & Development, LLC
Phase 3
655
Beijing, Changsha, Changzhou, Chengdu, Dazhou, Ganzhou, Guangzhou, Guiyang
2024-12-04
Not yet open
Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer
NCT06713057Locally Advanced Thyroid Gland Carcinoma, Thyroid Cancer
West China Hospital
Phase 2
20
Chengdu
2024-12-01
Recruiting
Observation of Pain During the Treatment of Great Saphenous Vein Using Microwave Ablation๏ผŒ and Analysis of Related Factors
NCT06693245Vascular Disease๏ผŒPeripheral, Venous Insufficiency of Leg, Varicose Veins of Lower Limb
Chengdu University of Traditional Chinese Medicine
Observational
155
Chengdu
2024-12-01
Recruiting
Comparative Analysis of Radiofrequency Ablation and Microwave Ablation Procedures for the Treatment of Small Saphenous Varicose Veins
NCT06711120Varicose Veins of Lower Limb, Venous Insufficiency of Leg, Vascular Disease๏ผŒPeripheral
Chengdu University of Traditional Chinese Medicine
Not applicable
150
Chengdu
2024-12-01
Recruiting
A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma
NCT06684639Neuroblastoma
The General Hospital of Western Theater Command
Phase EARLY_PHASE1
30
Chengdu
2024-12-01
Recruiting
Different Doses of Sirolimus for the Treatment of Cystic Lymphatic Malformations
NCT06673290Lymphatic Malformation
West China Hospital
Phase 2/3
150
Chengdu
2024-11-30
Recruiting
A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma
NCT06700395Multiple Myeloma
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
136
Shanghai, Chengdu
2024-11-28
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
AstraZeneca
Phase 2
270
Chengdu, Guangzhou, Nanchang, Nanjing, Nantong, Shandong, Shanghai, Tianjin
2024-11-27
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647Non-squamous Non-small Cell Lung Cancer
AstraZeneca
Phase 3
1,160
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-11-27
Recruiting
A Phase โ…ข Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06532006Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
Shanghai Henlius Biotech
Phase 3
550
Baise City, Beijing, Bengbu, Changchun, Changsha, Changzhi, Changzhou, Chengdu
2024-11-22
Recruiting
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
NCT06617325Systemic Lupus Erythematosus
UCB Biopharma SRL
Phase 3
450
Baotou, Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Guangzhou
2024-11-21
Active, closed
Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer
NCT06693128Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Ruijin Hospital
Phase 2
80
Chengdu, Shanghai, Yantai
2024-11-21
Active, closed
A Multi-centered๏ผŒRandomized๏ผŒDouble-blind๏ผŒPlacebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma
NCT06653322Asthma With Eosinophilic Phenotype
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 3
401
Chengdu
2024-11-21
Recruiting
Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study
NCT07020247Locally Advanced Rectal Cancer (LARC), Immunotherapy, Radiotherapy, Total Neoadjuvant Therapy
West China Hospital
Phase 3
184
Chengdu
2024-11-19
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
AstraZeneca
Phase 3
1,160
Beijing, Changchun, Changde, Changsha, Chengdu, Chongqing, Dalian, Guangzhou
2024-11-18
Recruiting
Neoadjuvant Chemoradiotherapy Compared to Neoadjuvant Chemotherapy for Luminal-Type Locally Advanced Breast Cancer: A Clinical Study
NCT06697938Breast Cancer
Sichuan Cancer Hospital and Research Institute
Not applicable
148
Chengdu
2024-11-18
Active, closed
An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma Patients
NCT06605885Asthma
AstraZeneca
Observational
202
Hohhot, Beijing, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou
2024-11-14
Active, closed
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
NCT06616532SCLC
Biotheus Inc.
Phase 3
404
Binzhou, Changchun, Changsha, Chengdu, Chenzhou, Chongqing, Dalian, Foshan
2024-11-13
Recruiting
A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors
NCT06618651Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
162
Chengdu
2024-11-13
Recruiting
Evaluating the Safety and Effectiveness of 5G Cloud Follow-up for Cardiovascular Implantable Electronic Devices
NCT06652750Sick Sinus Syndrome, Atrioventricular Block, Second and Third Degree, Heart Failure
The Third People's Hospital of Chengdu
Not applicable
688
Guangzhou, Chengdu
2024-11-13
Recruiting
LIVERAGEโ„ข - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457Metabolic Dysfunction Associated Steatohepatitis
Boehringer Ingelheim
Phase 3
1,590
Beijing, Changchun, Changsha, Changzhou Shi, Chengdu, Chongqing, Foshan, Fuzhou
2024-11-12
Recruiting
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
NCT07433283Tumor, Solid, Lung Cancer, Pancreas Cancer, Thyroid Cancer
Sichuan Enray Pharmaceutical Sciences Company
Phase 1/2
54
Beijing, Hunan, Chongqing, Fuzhou, Haikou, Heilongjiang, Shanghai, Chengdu
2024-11-12
Active, closed
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
NCT06537414Chronic Hepatitis B Virus Infection, Hepatitis B
GlaxoSmithKline
Phase 2
283
Beijing, Chengdu, Guangzhou, Shanghai
2024-11-11
Recruiting
Predicting Tumor Origin Based on Deep Learning of Lymph Node Puncture Cytology
NCT06810349Lymph Nodes With Tumor Metastasis
West China Hospital
Observational
10,000
Chengdu
2024-11-11
Not yet open
Placebo Response of Different Types of Sham Acupuncture for Knee Osteoarthritis
NCT06675981Knee Osteoarthritis
West China Hospital
Not applicable
150
Nanchang, Chengdu
2024-11-10
Recruiting
A Randomized Controlled Trial of a Web-based Platform for Cancer Pain Management
NCT06663956Cancer Pain
West China Hospital
Phase 3
100
Chengdu
2024-11-10
Active, closed
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319Asthma
Sanofi
Phase 2
556
Beijing, Changchun, Chengde, Chengdu, Foshan, Guangzhou, Guiyang, Hangzhou
2024-11-07
Active, closed
Using a Novel Balloon-shaped Large-Focal Pulsed Field Ablation Catheter in Persistent Atrial Fibrillation
NCT07294742Persistent Atrial Fibrillation
The Third People's Hospital of Chengdu
Not applicable
34
Chengdu
2024-11-06
Recruiting
Planed Organ Preservation for Low Rectal Cancer After Neoadjuvant Chemotherapy (OPLAR)
NCT07070622Rectal Cancer
West China Hospital
Phase 3
186
Chengdu
2024-11-01
By invitation
Minimal Vitrectomy and ILM Flap with Sodium Hyaluronate Gel for MH
NCT06685328Macular Hole, Macular Hole Surgery, Idiopathic Macular Hole, Macular Hole of Left Eye (Disorder)
Jie Zhong
Not applicable
52
Chengdu
2024-11-01
Not yet open
Preventing Perinatal Depression with an App-Based CBT Program
NCT06672432Perinatal Depression, Disease Prevention
Jintang County Maternal and Child Health Hospital
Not applicable
290
Chengdu
2024-11
Recruiting
A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNฮฑ in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)
NCT06650852Chronic Hepatitis B Virus (HBV) Infection
Brii Biosciences Limited
Phase 2
250
Beijing, Guangzhou, Shenzhen, Shanghai, Chengdu, Hangzhou
2024-10-31
Recruiting
A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy
NCT06676007IgA Nephropathy (IgAN), Early Initial Therapy
Sichuan Provincial People's Hospital
Observational
200
Chengdu
2024-10-30
Active, closed
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06711900Non-Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
432
Beijing, Changchun, Changcun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou
2024-10-30
Rows per page Showing 601–700 of 1291
Previous 5 6 7 8 9 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/chengdu?page=7

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,291 of those studies with a site in Chengdu.

How many clinical trials are recruiting in Chengdu?

732 of the 1,291 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 177 have not yet opened recruitment, 354 are active but closed to new participants, and 28 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.